Compositions and methods for preventing and treating graft versus host disease
AssigneesThe University of North Carolina at Chapel Hill, Regents of the University of Minnesota
InventorsJonathan Serody, James Coghill, Danny Bruce, Bruce Blazar, Heather Stefanski, Benjamin Vincent
Life of this patent
Estimating the term…
Abstract
ILC2 cells play a role in the pathogenesis of graft versus host disease (GvHD) and idiopathic pneumonia syndrome (IPS), both conditions associated with allogeneic stem cell transplantation. Infusion of IL-33 activated ILC2 cells into patients with ongoing GvHD or IPS, or prior to onset of GvHD or IPS in susceptible patients, substantially ameliorates the disease and improves survival.
Claims31
A pharmaceutical composition for treating graft versus host disease (GvHD) or idiopathic pneumonia syndrome (IPS), the composition comprising:
- a therapeutically effective amount of a cell preparation of IL-33 activated type 2 innate immune cells (ILC2);
- and
- a pharmaceutically acceptable carrier.
An in vitro method for generating activated ILC2 cells, comprising:
- collecting human cord blood from a subject;
- isolating c-Kit positive cells from the cord blood;
- and
- culturing the c-Kit positive cells in the presence of an IL-33 cytokine, whereby IL-33 activated ILC2 cells are generated.
A method for treating graft versus host disease (GvHD) or idiopathic pneumonia syndrome (IPS) in a subject, comprising:
- providing a subject in need of treatment for GvHD and/or IPS;
- and
- administering to the subject a therapeutically effective amount of a cell preparation of IL-33 activated ILC2 cells.
A method for preventing GvHD or IPS in a subject, comprising:
- providing a subject receiving allo-SCT or allo-BMT;
- and
- administering to the subject a therapeutically effective amount of a cell preparation of IL-33 activated ILC2 cells.
A method of increasing production of Th2 cytokines in a subject, comprising:
- providing a subject in need of increased Th2 cytokine production;
- and
- administering to the subject a therapeutically effective amount of a cell preparation of IL-33 activated ILC2 cells.
Dependencies are inferred from the claim text.